Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study.
Roviello G, Petrioli R, Nardone V, Rosellini P, Multari AG, Conca R, Aieta M. Roviello G, et al. Among authors: multari ag. Medicine (Baltimore). 2018 May;97(20):e10745. doi: 10.1097/MD.0000000000010745. Medicine (Baltimore). 2018. PMID: 29768350 Free PMC article. Clinical Trial.
New molecular therapies in patients with advanced Hepatocellular Cancer in second line of treatment: Is a real defeat?: Results from a literature based meta-analysis of randomized trials.
Roviello G, Zanotti L, Cappelletti MR, Gobbi A, Borsella G, Pacifico C, Multari AG, Generali D. Roviello G, et al. Among authors: multari ag. Crit Rev Oncol Hematol. 2016 Dec;108:62-68. doi: 10.1016/j.critrevonc.2016.10.015. Epub 2016 Oct 29. Crit Rev Oncol Hematol. 2016. PMID: 27931841 Review.
The prognostic value of CD3+ tumor-infiltrating lymphocytes for stage II colon cancer according to use of adjuvant chemotherapy: A large single-institution cohort study.
Francini E, Ou FS, Lazzi S, Petrioli R, Multari AG, Pesola G, Messuti L, Colombo E, Livellara V, Bazzurri S, Cherri S, Miano ST, Wolfe EG, Alberts SR, Hubbard JM, Yoon HH, Francini G. Francini E, et al. Among authors: multari ag. Transl Oncol. 2021 Feb;14(2):100973. doi: 10.1016/j.tranon.2020.100973. Epub 2020 Dec 15. Transl Oncol. 2021. PMID: 33338878 Free PMC article.
Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program.
Procopio G, Prisciandaro M, Iacovelli R, Cortesi E, Fornarini G, Facchini G, Cartenì G, Sabbatini R, Del Bene G, Galli L, Caserta C, Multari AG, Bregni M, Massari F, Buti S, De Giorgi U, Zustovich F, Milella M, Calabrò F, Mancini ML, Tortora G, Vernieri C, Santini D, Sorarù M, Ricotta R, Masini C, Tucci M, Fedeli SL, Ortega C, Mecozzi A, Ratta R, Sternberg CN, Verzoni E. Procopio G, et al. Among authors: multari ag. Clin Genitourin Cancer. 2018 Aug;16(4):e945-e951. doi: 10.1016/j.clgc.2018.03.014. Epub 2018 Apr 19. Clin Genitourin Cancer. 2018. PMID: 29753637